Talis Biomedical

Talis Biomedical Assets per Share

Delisted

The Total Assets per Share of Talis Biomedical (TLIS) as of Oct 30, 2026 is 52.02 USD. In the previous year, Total Assets per Share was 93.02 USD — a change of -44.08% (lower).

Assets per Share

52.02USD

YoY

-44.08%

Last updated:

Total Assets per Share of Talis Biomedical is 2023 52.02 USD. Total Assets per Share of Talis Biomedical was 2022 93.02 USD. It decreases by -44.08% lower compared to the previous year.

The Talis Biomedical Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
6.25 USD
Jan 1, 2019
14.14 USD
Jan 1, 2020
109.01 USD
Jan 1, 2021
146.06 USD
Jan 1, 2022
93.02 USD
Jan 1, 2023
52.02 USD
The Talis Biomedical Assets per Share history
YEARAssets per ShareYoY
52.02USD-44.08%
93.02USD-36.32%
146.06USD+33.98%
109.01USD+671.01%
14.14USD+126.16%
6.25USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Talis Biomedical Stock analysis

What does Talis Biomedical do? Talis Biomedical Corp develops and commercializes the Talis One system, a cloud-enabled molecular diagnostic platform comprising a compact instrument, single-use test cartridges, and software linked to a central cloud database. The company targets healthcare providers seeking point-of-care molecular testing for infectious diseases, respiratory infections, women's health conditions, and sexually transmitted infections (STIs). Its products include assay kits for respiratory panels combining influenza A, influenza B, and COVID-19 tests, designed for use by untrained personnel. Revenue is generated through sales of the Talis One system and associated assay kits to healthcare facilities requiring rapid, accurate diagnostic solutions. The Talis One system is positioned for central laboratory-level accuracy at the point of care, appealing to clinics and hospitals needing efficient diagnostic tools. The Respiratory Panel, integrating influenza A, influenza B, and COVID-19 assays, addresses high-demand areas in infectious disease testing. The company's focus on women's health and STI-related assays expands its market reach within specialized healthcare segments. Sales of these products are directed toward healthcare providers who prioritize accessible, user-friendly diagnostic technology without requiring extensive training. Talis Biomedical Corp's commercial strategy centers on delivering diagnostic solutions that combine advanced molecular testing with ease of use. The Talis One system and its assay kits are marketed to healthcare facilities aiming to enhance diagnostic capabilities at the point of care. By targeting respiratory infections, women's health, and STIs, the company addresses key areas where rapid, accurate testing is critical. Revenue streams are derived from the sale of both the hardware platform and the consumable test kits, ensuring ongoing customer engagement through recurring purchases. Talis Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talis Biomedical stock

Total Assets per Share of Talis Biomedical is 52.02 USD in 2023.

Total Assets per Share of Talis Biomedical changed from 93.02 USD to 52.02 USD, representing a -44.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Talis Biomedical since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Talis Biomedical

All Key Metrics — Talis Biomedical